Last reviewed · How we verify
Xeruborbactam Oral Prodrug
At a glance
| Generic name | Xeruborbactam Oral Prodrug |
|---|---|
| Also known as | QPX7831, QPX7831 Placebo |
| Sponsor | Qpex Biopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants (PHASE1)
- PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeruborbactam Oral Prodrug CI brief — competitive landscape report
- Xeruborbactam Oral Prodrug updates RSS · CI watch RSS
- Qpex Biopharma, Inc. portfolio CI